A Phase 1, open label, dose escalation study of the safety, tolerability and preliminary efficacy of intraperitoneal EGEN-001 in patients with recurrent epithelial ovarian cancer.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2013
At a glance
- Drugs GEN 1 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 27 Feb 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 13 Jul 2007 New trial record.